Champion Investments Acquires an Equity Interest in Dakota Life Sciences

Dakota LogoChampion Investments, Inc. (CHAM OTC:PK) is pleased to announce the acquisition of an equity interest in Dakota Life Sciences, an anti-infective private pharmaceutical Company with award-winning products designed to provide the highest efficacy for global patients at high risk of suffering from dangerous microbial and fungal infections.

The Company was founded based on its topical penetrating technology for drug delivery. That technology, referred to as Site Specific Penetration Technology (SSPT™) has received multiple prestigious awards such as the Edison Award for Innovation; Stevie Award for Innovation; and the Best Pharmaceutical of 2012 by the leading retail pharmaceutical publication, Drug Store News.

Steven Morgan, Founder and Chief Executive Officer of Champion Investments, Inc. said, “We are excited to add Dakota Life Sciences to our investment portfolio and believe their growth in these markets will be financially rewarding for not only Dakota Life Sciences but also Champion Investments shareholders.”

About Champion Investments

Champion Investments, Inc. (CHAM OTC:PK) is a publicly-traded corporation that intends to be treated as a Business Development Company and is headquartered in Houston, Texas. The Company makes investments in US-based early stage, emerging and small to middle-market enterprises in the technology, medical, life sciences and consumer sectors.

About Dakota Life Sciences

Dakota Life Sciences is a life science organization specializing in technologies and products designed to meet unmet needs in specific growth markets, with an emphasis in wound care.  The Company’s expected initial product launch in 2016 will be an FDA-regulated OTC patented ThinNail® brand anti-fungal nail product.  In 2014, the Company’s legal entity (Thru Pharma, LLC) acquired controlling interest in a public shell company, Arax Holdings, Inc. (“ARAT”), listed on the OTCQB public exchange. Arax Holdings Corporation is a fully reporting, DTC eligible company. Since that acquisition, various PIPE investments have occurred with accredited investors.

CI Logo CIFor more information please contact:
Dr. Kerri Shomette, Vice President, Investor Relations email: Telephone: 214.446.5699